Top Markets
Coin of the day
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
Pozycja w akcjach #40823
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Cena akcji
$0.00918474
Kapitalizacja rynkowa
$76.44K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
38.04%
Kraj
GB
Handel Thalia Therapeutics Plc (THAT)

Kategoria

EPS dla Thalia Therapeutics Plc (THAT)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Thalia Therapeutics Plc, obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Thalia Therapeutics Plc od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów